What is the recurrence rate of malignant phyllodes tumors (Phyllodes tumor) post-operation without radiotherapy (radiation therapy)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recurrence Rate of Malignant Phyllodes Tumors Without Radiotherapy

The recurrence rate of malignant phyllodes tumors after surgery without radiotherapy is approximately 25%, with local recurrence occurring in about 12% of cases at 10 years when adequate surgical margins are achieved. 1, 2

Overall Recurrence Rates by Histologic Grade

The pooled recurrence rates from real-world evidence demonstrate a clear gradient based on tumor grade 1:

  • Benign phyllodes: 7.1%
  • Borderline phyllodes: 16.7%
  • Malignant phyllodes: 25.1%

These rates represent patients treated with surgery alone, without routine adjuvant radiotherapy 1.

Impact of Surgical Margins on Recurrence

Margin status is the single most critical modifiable factor determining recurrence risk, more important than histologic subtype 3, 4:

  • Positive or ≤1 mm margins: Dramatically increased recurrence risk, with 10 of 11 locally recurrent tumors having inadequate margins at initial surgery 5
  • 1 mm margins: Odds ratio of 0.4 for recurrence compared to wider margins 1
  • ≥1 cm margins: Recommended target to minimize local recurrence 3, 4, 6

Close or positive margins (p = 0.001) were significantly associated with increased locoregional recurrence on univariable analysis 2.

Timing and Pattern of Recurrence

Local recurrence typically occurs after a median interval of 20 months, though malignant tumors tend to recur earlier than benign or borderline subtypes 7:

  • 10-year cumulative locoregional recurrence incidence: 12% in malignant/borderline phyllodes tumors 2
  • Distant metastases occur exclusively in malignant phyllodes tumors, with a 10-year distant recurrence-free survival of 94% 2

High-Risk Features Predicting Poor Outcomes

Uniformly poor pathologic features identify a subset of malignant phyllodes with dramatically worse prognosis 2:

The presence of ALL of the following features predicts poor outcomes:

  • Marked stromal cellularity
  • Stromal overgrowth
  • Infiltrative borders
  • ≥10 mitoses per 10 high-power fields

All distant recurrences occurred in patients with these uniformly poor features (20% of malignant phyllodes), with 10-year disease-specific survival of only 66% compared to 100% in those without these features 2.

Additional Independent Prognostic Factors

Beyond margin status, the following clinicopathological features independently predict recurrence 1:

  • Moderate or severe stromal atypia and hypercellularity
  • Stromal overgrowth
  • Mitotic count ≥5 per 10 high-power fields
  • Tumor necrosis
  • Infiltrative tumor borders

Notably, tumor size ≥5 cm was NOT an independent prognostic factor for recurrence 1.

Role of Radiotherapy in Reducing Recurrence

While the question asks about recurrence without radiotherapy, it's critical to note that adjuvant radiotherapy significantly reduces recurrence rates in malignant phyllodes tumors (p = 0.034) but not in borderline or overall phyllodes populations 1:

  • The NCCN recommends considering radiotherapy specifically for malignant tumors >5 cm, infiltrative margins, or cases where clear margins could not be achieved 3, 4, 6
  • Radiotherapy improves local control but not overall survival 6

Critical Clinical Pitfalls

Do NOT accept inadequate surgical margins - this is the most important modifiable factor for preventing local recurrence 3, 5:

  • Re-excision should be performed for positive margins
  • Target ≥1 cm margins at initial surgery

Younger age (<40 years) is associated with increased locoregional recurrence risk (p = 0.02), requiring more vigilant follow-up 2.

Malignant recurrence can occur from initially benign or borderline tumors in 19% of recurrent cases, though no significant predictive factors were identified 7.

References

Research

Management of phyllodes tumor: A systematic review and meta-analysis of real-world evidence.

International journal of surgery (London, England), 2022

Guideline

Diagnostic Criteria and Treatment of Phyllodes Tumors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosis and Management of Recurrent Phyllodes Tumors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Phyllodes Tumors-The Predictors and Detection of Recurrence.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2021

Guideline

Treatment of Borderline Phyllodes Tumors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.